Molecular and Host Lifestyle Factors Associated with Persistent Human Papillomavirus Infection and Progression into Cervical Cancer: A Literature Review

Edward Christopher Yo, Kartiwa Hadi Nuryanto

Abstract


Background: Human papillomavirus (HPV) infection is the most common sexually transmitted infection (STI) worldwide, especially among low- and middle-income countries. The virus can establish persistent infection in the cervical epithelium, thereby increasing the risk of progression into cervical cancer. Since cervical cancer is one of the leading causes of cancer death among women worldwide, it is important to understand more about persistent HPV infection and potential therapeutic targets to suppress it. This study aims to summarize current insight into various molecular and host lifestyle factors that contribute to persistent HPV infection and ultimately cervical cancer.

 

Methods: This study adopts a literature review design by conducting a journal search through Google Scholar, PubMed, and ScienceDirect. The keywords used included “human papillomavirus”, “persistent infection”, “cervical cancer”, “immune evasion”, and “lifestyle”.

 

Results: Several diverse mechanisms are believed to facilitate persistent HPV infection, which can be classified under molecular and host lifestyle factors. Molecular factors include compartmentalization of HPV replication and gene expression as well as immune evasion, whereas host lifestyle factors include alcohol consumption, smoking, multiple sexual partners, STI coinfection, and certain contraceptive agents.

 

Conclusion: Persistent HPV infection acts as the intermediate phenotype before developing into cervical cancer. Understanding the molecular factors as well as host lifestyle factors underlying it can lead to more specific therapeutic options as well as better prevention and education programs. Future research is needed to better clarify the exact mechanisms underlying persistent infection.

 


Keywords


cervical cancer, human papillomavirus, immune evasion, lifestyle, persistent infection

Full Text: View | Download

DOI: 10.33371/ijoc.v18i2.1068

Article Metrics

Abstract View: 90,
PDF Download: 30
             

References


Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female reproductive health. Nat Microbiol. 2022; 7(8): 1116–1126.

Kops NL, Bessel M, Horvath JDC, et al. Factors associated with HPV and other self-reported STI coinfections among sexually active Brazilian young adults: cross-sectional nationwide study. BMJ Open. 2019; 9(6): e027438.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–249.

Bodily J, Laimins LA. Persistence of human papillomavirus infections: keys to malignant progression. Trends Microbiol. 2011; 19(1): 33–39.

Kashyap N, Krishnan N, Kaur S, et al. Risk factors of cervical cancer: a case-control study. Asia Pac J Oncol Nurs. 2019; 6(3): 308–314.

Tekalegn Y, Sahiledengle B, Woldeyohannes D, et al. High parity is associated with increased risk of cervical cancer: systematic review and meta-analysis of case–control studies. Womens Health (Lond Engl). 2022; 18: 17455065221075904.

Gadducci A, Cosio S, Fruzzetti F. Estro-progestin contraceptives and risk of cervical cancer: a debated issue. Anticancer Research. 2020; 40: 5995–6002.

Sudenga SL, Shrestha S. Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. International Journal of Infectious Diseases. 2013; 17(4): e216–e220.

Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011; 103: 368–383.

Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses. 2017; 9(8): 229.

Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila). 2012; 5(1): 18–23.

Gravitt PE, Winer RL. Natural history of HPV infection across the lifespan: role of viral latency. Viruses. 2017; 9(10): 267.

Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012; 25(2): 215–222.

Graham SV. Keratinocyte differentiation-dependent human papillomavirus gene regulation. Viruses. 2017; 9: 245.

Bedell MA, Hudson JB, Golub TR, et al. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol. 1991; 65: 2254–2260.

Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol. 2008; 109: S15-21.

Groves IJ, Coleman N. Pathogenesis of human papillomavirus-associated mucosal disease. J Pathol. 2015; 235: 527–538.

Zhou C, Tuong ZK, Frazer IH. Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol. 2019; 9: 682.

Miller LS. Toll-like receptors in skin. Adv Dermatol. 2008; 24: 71–87.

Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res. 2009; 130: 266–276.

Alcocer-González JM, Berumen J, Taméz-Guerra R, et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol. 2006; 19: 481–491.

Hubert P, Caberg J-H, Gilles C, et al. E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirus-associated (pre)neoplastic lesions. J Pathol. 2005; 206: 346–355.

Le Borgne M, Etchart N, Goubier A, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity. 2006; 24: 191–201.

Oh HY, Kim MK, Seo S, et al. Alcohol consumption and persistent infection of high-risk human papillomavirus. Epidemiol Infect. 2015; 143(7): 1442–1450.

Sanjoaquin MA, Allen N, Couto E, et al. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer. 2005; 113: 825–828.

Pöschl G, Stickel F, Wang XD, et al. Alcohol and cancer: genetic and nutritional aspects. Proc Nutr Soc. 2004; 63: 65–71.

Li Y, Yang A, Wang W, et al. Folic acid intake and folate status and risk of cervical cancer: a systematic review and meta-analysis from 20 independent case-control studies and 4 RCTs. Curr Dev Nutr. 2020; 4: 330.

Schmeink CE, Melchers WJG, Siebers AG, et al. Human papillomavirus persistence in young unscreened women, a prospective cohort study. PLoS One. 2011; 6(11): e27937.

Utami TW, Kusuma F, Winarto H, et al. Tobacco use and its association with HPV infection in normal uterine cervix: a study from a Sustainable Development Goals perspective. Tob Induc Dis. 2021; 19: 64.

Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer. 2010; 126: 684–691.

Bae J, Seo SS, Park YS, et al. Natural history of persistent high-risk human papillomavirus infections in Korean women. Gynecol Oncol. 2009; 115: 75–80.

Nielsen A, Kjaer SK, Munk C, et al. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol. 2010; 82: 616–623.

Vaccarella S, Herrero R, Snijders PJF, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol. 2008; 37: 536–546.

Szarewski A, Maddox P, Royston P, et al. The effect of stopping smoking on cervical Langerhans’cells and lymphocytes. British Journal of Obstetrics and Gynaecology. 2001; 108: 295–303.

Williams J, Rakovac I, Loyola E, et al. A comparison of self-reported to cotinine-detected smoking status among adults in Georgia. Eur J Public Health. 2020; 30(5): 1007–1012.

Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer—a systematic review & meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020; 247: 163–175.

Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, et al. Oral contraceptives and cancer of the cervix uteri: a meta-analysis. Acta Obstet Gynecol Scand. 1992; 71: 368–376.

International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007; 370: 1609–1621.

Marks M, Gravitt PE, Gupta SB, et al. Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J Infect Dis. 2011; 204(10): 1505–1513.

Ramachandran B. Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis. Endocrine-Related Cancer. 2017; 24: R99–R108.

Green J, Berrington de Gonzalez A, Smith JS, et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer. 2003; 88: 1713–1720.

Bright PL, Turner AN, Morrison CS, et al. Hormonal contraception and area of cervical ectopy: a longitudinal assessment. Contraception. 2011; 84: 512–519.

Scott ME, Shvetsov YB, Thompson PJ, et al. Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer. 2013; 133: 1187–1196.

Shanmugasundaram U, Hilton JF, Critchfield JW, et al. Effects of the levonorgestrel‐releasing intrauterine device on the immune microenvironment of the human cervix and endometrium. Am J Reprod Immunol. 2016; 76: 137–148.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Edward Christopher Yo, Kartiwa Hadi Nuryanto

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.